Pfizer Animal Health’s FluSure XP vaccine, for use against H1N1 and H3N2 swine flu (SIV) strains, has been rolled into a pair of new combination products for the Canadian market.
The first, FluSure XP/FarrowSure Gold B, is registered for use in healthy breeding swine, including pregnant sows and gilts, the company said in a release Tuesday.
The company bills it as the only vaccine available in Canada to help prevent:
- respiratory disease caused by SIV subtypes H1N1 and H3N2,
- reproductive failure caused by porcine parvovirus (PPV), and
- disease caused by erysipelothrix rhusiopathiae and six serovars of leptospira.
Read Also
U.S. livestock: Cattle strength continues
Cattle futures on the Chicago Mercantile Exchange were stronger on Friday, hitting fresh highs to end the week.
Offspring of vaccinated sows also benefit from maternal antibodies through colostrum for SIV, the company said. FluSure XP/FarrowSure Gold B has shown an 18-week duration of immunity against erysipelas.
The second new product, FluSureXP/RespiSure, is registered in Canada for use in healthy swine of at least three weeks of age, including pregnant sows and gilts.
The vaccine helps prevent respiratory disease caused by SIV subtypes H1N1 and H3N2, and/or by mycoplasma hyopneumoniae, the company said.
FluSure XP/RespiSure, Pfizer said, has a duration of immunity of at least 10 weeks, based on “significantly reduced lung lesions,” against H3N2 swine flu.
“Protecting herds from influenza may not always be top of mind, and these new combination products make it easy and convenient to provide more complete protection with one product,” Walter Heuser, Pfizer’s swine business unit director, said in a release Tuesday.
Both products are available “exclusively through veterinarians,” the company said, adding it’s best for a hog producer to first discuss with his or her vet how the products would fit a farm’s vaccination protocol.
